Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/20718
Title: [Therapeutic update in hepatitis C].
Authors: 
Mesh: 
Issue Date: Sep-2015
Citation: Rev Esp Quimioter.2015 Sep;(28 Suppl 1):48-51
Abstract: Hepatitis C virus infection is a major health burden affecting 130-170 million people worldwide. Approximately 10-30% of those with chronic hepatitis C will progress to cirrhosis over 20-30 years. The development of new direct-acting antivirals has changed the management of the disease, allowing efficacious Interferon-free therapies superior to prior treatment regimens with minimal side effects, even in some subgroups previously thought to be difficult to cure such as cirrhotic patients.
PMID: 26365735
URI: https://hdl.handle.net/20.500.12530/20718
Appears in Collections:Hospitales > H. U. Clínico San Carlos > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. Clínico San Carlos > Artículos

Files in This Item:
The file with the full text of this item is not available due to copyright restrictions or because there is no digital version. Authors can contact the head of the repository of their center to incorporate the corresponding file.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.